These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 3501154)

  • 1. Successful treatment of esophageal dysmotility and Raynaud's phenomenon in systemic sclerosis and achalasia by transcutaneous nerve stimulation. Increase in plasma VIP concentration.
    Kaada B
    Scand J Gastroenterol; 1987 Nov; 22(9):1137-46. PubMed ID: 3501154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic sclerosis: successful treatment of ulcerations, pain, Raynaud's phenomenon, calcinosis, and dysphagia by transcutaneous nerve stimulation. A case report.
    Kaada B
    Acupunct Electrother Res; 1984; 9(1):31-44. PubMed ID: 6145309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcutaneous electrical nerve stimulation decreases lower esophageal sphincter pressure in patients with achalasia.
    Guelrud M; Rossiter A; Souney PF; Sulbaran M
    Dig Dis Sci; 1991 Aug; 36(8):1029-33. PubMed ID: 1864193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Esophageal motility in Raynaud's disease, systemic scleroderma and presclerodermal Raynaud's syndrome].
    Hostein J; Bost R; Carpentier P; Franco A; Fournet J
    Gastroenterol Clin Biol; 1985 Feb; 9(2):130-5. PubMed ID: 3979734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In search of mediators of skin vasodilation induced by transcutaneous nerve stimulation: III. Increase in plasma VIP in normal subjects and in Raynaud's disease.
    Kaada B; Olsen E; Eielsen O
    Gen Pharmacol; 1984; 15(2):107-13. PubMed ID: 6714637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Esophageal scintigraphy with a semisolid meal to evaluate esophageal dysmotility in systemic sclerosis and Raynaud's phenomenon.
    Bestetti A; Carola F; Conciato L; Marasini B; Tarolo GL
    J Nucl Med; 1999 Jan; 40(1):77-84. PubMed ID: 9935061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pathogenesis of esophageal dysfunction in scleroderma and Raynaud's disease.
    Cohen S; Fisher R; Lipshutz W; Turner R; Myers A; Schumacher R
    J Clin Invest; 1972 Oct; 51(10):2663-8. PubMed ID: 5056661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of transcutaneous nerve stimulation on esophageal motility in patients with achalasia and scleroderma.
    Mearin F; Zacchi P; Armengol JR; Vilardell M; Malagelada JR
    Scand J Gastroenterol; 1990 Oct; 25(10):1018-23. PubMed ID: 2263874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcutaneous electrical nerve stimulation (TENS) in Raynaud's phenomenon.
    Mulder P; Dompeling EC; van Slochteren-van der Boor JC; Kuipers WD; Smit AJ
    Angiology; 1991 May; 42(5):414-7. PubMed ID: 2035894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lower plasma levels of some gastrointestinal peptides in Raynaud's disease. Influence of transcutaneous nerve stimulation.
    Kaada B; Lygren I
    Gen Pharmacol; 1985; 16(2):153-6. PubMed ID: 3873378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment of itching and atopic eczema by transcutaneous nerve stimulation.
    Bjørnå H; Kaada B
    Acupunct Electrother Res; 1987; 12(2):101-12. PubMed ID: 2890272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of transcutaneous nerve stimulation on esophageal function in normal subjects--evidence for a somatovisceral reflex.
    Chang FY; Chey WY; Ouyang A
    Am J Chin Med; 1996; 24(2):185-92. PubMed ID: 8874676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spinal cord stimulation for the treatment of progressive systemic sclerosis and Raynaud's syndrome.
    Francaviglia N; Silvestro C; Maiello M; Bragazzi R; Bernucci C
    Br J Neurosurg; 1994; 8(5):567-71. PubMed ID: 7857537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measurement of cold challenge responses in primary Raynaud's phenomenon and Raynaud's phenomenon associated with systemic sclerosis.
    O'Reilly D; Taylor L; el-Hadidy K; Jayson MI
    Ann Rheum Dis; 1992 Nov; 51(11):1193-6. PubMed ID: 1466594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low molecular weight dextran infusions in systemic sclerosis with Raynaud's phenomenon: a report of nine cases.
    Lane P
    Br Med J; 1970 Dec; 4(5736):657-9. PubMed ID: 5488384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in red cell behaviour between patients with Raynaud's phenomenon and systemic sclerosis and patients with Raynaud's disease.
    Rustin MH; Kovacs IB; Sowemimo-Coker SO; Maddison PJ; Kirby JD
    Br J Dermatol; 1985 Sep; 113(3):265-72. PubMed ID: 3877518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis.
    Rosato E; Letizia C; Proietti M; Aversa A; Menghi G; Rossi C; Torella E; Cotesta D; Petramala L; Bruzziches R; Spera G; Pisarri S; Salsano F
    J Biol Regul Homeost Agents; 2009; 23(1):23-9. PubMed ID: 19321043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of nasal CPAP on nocturnal reflux in patients with aperistaltic esophagus.
    Shoenut JP; Kerr P; Micflikier AB; Yamashiro Y; Kryger MH
    Chest; 1994 Sep; 106(3):738-41. PubMed ID: 8082351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hand warming as a treatment for Raynaud's phenomenon in systemic sclerosis.
    Goodfield MJ; Rowell NR
    Br J Dermatol; 1988 Nov; 119(5):643-6. PubMed ID: 3207617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Raynaud phenomenon and ischemic ulcers associated to systemic sclerosis with hyperbaric oxygen.
    Ahijón-Lana M; Baragaño-Ordóñez E; Veiga-Cabello R; de la Cruz-Tapidor C; Carreira PE
    Reumatol Clin (Engl Ed); 2022 Apr; 18(4):246-248. PubMed ID: 34953734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.